Advances in Hematology / 2009 / Article / Tab 1

Research Article

Screening for Residual Disease in Pediatric Burkitt Lymphoma Using Consensus Primer Pools

Table 1

Persistent or minimal residual disease assessment using real-time and PSP assays.

Case (Dx) Real-time results/PSP results & clinical status*
Entry1 Mo2 Mo3-4 MoClinical status

NHL-1 (BL)Tissue (+/PSP)CR (End of Rx))
Blood (+/+) Blood (−/−)Blood (+/+) Blood (−/−)

NHL-2 (BL)Tissue (+/PSP)CR (End of Rx)
Blood (+/+)Blood (+/+)Blood (−/−)
BMA (+/+)

NHL-3 (BL)Tissue (+/PSP)Dead (Infection; 3 mo)
Blood (+/+)Blood (+/+)
BMA (+/+)BMA (−/−)

NHL-4 (BL)Tissue (+/PSP) CR ( End of Rx )
Blood (+/+)Blood (+/+)Blood (−/−)

NHL-5 (BL)Tissue (+/PSP)BMA relapse (6 mo)
Blood (+/+)Blood (−/−)
BMA (+/+)BMA (+/+)

NHL-6 (BL)Tissue (+/PSP)CR ( End of Rx )
BMA (+/+)BMA (−/−)

NHL-7 (BL)Tissue (+/PSP)BMA relapse (3 mo)
BMA (+/+)BMA (+/+)

NHL-8 (BL)Tissue (+/PSP)
Blood (+/+)Blood (−/−)Blood (−/−)CR (End of Rx)

NHL-9 (BL)Tissue (+/PSP)
Blood (+/+)Blood (+/+)Blood (−/−)CR (End of Rx)
CSF (+/+)CSF (=/=)

NHL-10 (BL)Tissue (+/PSP)
Blood (+/+)Blood (−/−)CR (End of Rx)

NHL-11 (BL)Tissue (+/PSP)
Blood (+/+)Blood (+/+)Blood (+/+)Blood (−/−)CR (End of Rx)

NHL-12 (BL)Tissue (+/PSP)
Blood (+/+)Blood (+/+)Blood (−/−)CR (End of Rx)
BMA (Equiv)BMA (+/+)BMA (−/−)
CSF (+/+)

NHL-13 (BL)Tissue (+/PSP)
Blood (+/+)Blood (=/=)Blood (=/=)
BMA (+/+)BMA(−/−)CR (End of Rx)

NHL-14 (BL)Tissue (+/PSP)
Blood (+/+)Blood (−/−)Blood (−/−)CR (End of Rx)
BMA (+/+)

Specimens were not available from some time points; Dx: diagnosis; BL: Burkitt lymphoma; BMA: bone marrow aspirate; real-time results/patient-specific primer (PSPs) results: Positive (+), Negative (−), or Equivocal (=) for each assay result; CR: complete remission; End of Rx: End of therapy.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.